Pharmafile Logo
T40 2022 Cover
Diversity, Equity and Inclusion
Communiqué 53 Cover Image
- PMLiVE

eosinophilic

Teva Pharma logo

Teva scales back R&D as Copaxone competition looms

Copaxone accounts for almost 40% of its revenue

- PMLiVE

EMA draws fire on new clinical reports policy

Has recently come under pressure from transparency groups

Medical device firms told to address cybersecurity risks

FDA says online security should be part of a device's design and development

Sanofi reception

Trial suggests Sanofi’s asthma drug works in sinusitis

Dupilumab able to reduce polyp size in sinusitis patients

- PMLiVE

FDA awards $19m in rare disease grants

US regulator supports 15 orphan drug projects

- PMLiVE

EMA to review experimental Ebola drugs

Response comes as death-toll tops 3,000

- PMLiVE

EMA wants to embed patient viewpoint within drug assessment

Will pilot CHMP benefit-risk evaluation project

Gilead Sciences

Gilead’s hep C combination Harvoni recommended for EU approval

CHMP backs combination of Sovaldi and ledipasvir

EU flag

EMA backs 15 new medicines for use in EU

Includes new treatments from Gilead, Lilly, Boehringer, AstraZeneca and Janssen

- PMLiVE

Humira gets FDA nod for paediatric Crohn’s disease

Can be used as treatment for patients as young as six

- PMLiVE

Celgene’s Otezla gains new US psoriasis approval

FDA backs oral drug in moderate to severe plaque psoriasis

- PMLiVE

FDA approves Lilly’s GLP-1 diabetes drug Trulicity

The once-weekly treatment is set to compete with Bydureon, Tanzeum and Victoza

Subscribe to our email news alerts

Latest jobs from #PharmaRole

Latest content

Latest intelligence

Quick links